Novartis Prepares For Diovan Patent Expiries; Looks To New Product Launches
Executive Summary
Novartis is shifting its marketing muscle away from the mega-drug Diovan and encouraging new hypertensive patients to take Tekturna or Exforge in hopes of forestalling generic competition that will begin to surface in two years, according to Joe Jimenez, who heads the pharmaceuticals business
You may also be interested in...
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.